JACC:联合冠脉CTA可改善冠心病预后

2019-10-21 不详 MedSci原创

在SCOT-HEART临床试验中,冠脉CTA的运用可以减少稳定型胸痛患者的心源性死亡率。本研究的目的旨在评估该临床试验的五年临床结局及可能机制。本研究将4146名患者随机分成标准治疗组和标准治疗联合冠脉CTA组。在未被诊断为冠心病心绞痛的患者中,冠脉CTA可以降低主要终点事件发生率(p < 0.001)。在接受冠脉CTA检测患者中,第一年的冠脉血运重建率更高( [HR]: 1.21; 95%

在SCOT-HEART临床试验中,冠脉CTA的运用可以减少稳定型胸痛患者的心源性死亡率。本研究的目的旨在评估该临床试验的五年临床结局及可能机制。

本研究将4146名患者随机分成标准治疗组和标准治疗联合冠脉CTA组。在未被诊断为冠心病心绞痛的患者中,冠脉CTA可以降低主要终点事件发生率(p < 0.001)。在接受冠脉CTA检测患者中,第一年的冠脉血运重建率更高( [HR]: 1.21; 95% CI: 1.01-1.46; p = 0.042),但在一年后有所降低(HR: 0.59; 95% CI: 0.38-0.90; p = 0.015)。接受冠状动脉CTA的患者在整个随访期间的预防性治疗率更高(p < 0.001)。

研究结果显示,冠状动脉CTA能更好地针对冠心病患者进行预防性治疗,从而改善冠心病预后。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849784, encodeId=f7db1849e845c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Dec 16 08:49:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854545, encodeId=f19a185454543, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Feb 02 02:49:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326371, encodeId=380413263e113, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493774, encodeId=15d21493e74c8, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630059, encodeId=a95f1630059a2, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374195, encodeId=58e63e419503, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Oct 21 22:11:39 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-12-16 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849784, encodeId=f7db1849e845c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Dec 16 08:49:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854545, encodeId=f19a185454543, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Feb 02 02:49:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326371, encodeId=380413263e113, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493774, encodeId=15d21493e74c8, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630059, encodeId=a95f1630059a2, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374195, encodeId=58e63e419503, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Oct 21 22:11:39 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2020-02-02 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849784, encodeId=f7db1849e845c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Dec 16 08:49:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854545, encodeId=f19a185454543, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Feb 02 02:49:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326371, encodeId=380413263e113, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493774, encodeId=15d21493e74c8, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630059, encodeId=a95f1630059a2, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374195, encodeId=58e63e419503, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Oct 21 22:11:39 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849784, encodeId=f7db1849e845c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Dec 16 08:49:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854545, encodeId=f19a185454543, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Feb 02 02:49:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326371, encodeId=380413263e113, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493774, encodeId=15d21493e74c8, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630059, encodeId=a95f1630059a2, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374195, encodeId=58e63e419503, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Oct 21 22:11:39 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849784, encodeId=f7db1849e845c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Dec 16 08:49:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854545, encodeId=f19a185454543, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Feb 02 02:49:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326371, encodeId=380413263e113, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493774, encodeId=15d21493e74c8, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630059, encodeId=a95f1630059a2, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374195, encodeId=58e63e419503, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Oct 21 22:11:39 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-10-23 许安
  6. [GetPortalCommentsPageByObjectIdResponse(id=1849784, encodeId=f7db1849e845c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Dec 16 08:49:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854545, encodeId=f19a185454543, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Feb 02 02:49:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326371, encodeId=380413263e113, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493774, encodeId=15d21493e74c8, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630059, encodeId=a95f1630059a2, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Wed Oct 23 07:49:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374195, encodeId=58e63e419503, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Oct 21 22:11:39 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-10-21 qingfengqishi5

    学习了,学习了

    0

相关资讯

JACC:植入式心脏预警仪明显减少急性冠脉综合征就诊的延误时间

住院前急性冠脉综合征(ACS)事件的时间耽搁会恶化患者的预后,本研究的目的旨在评估植入式心脏监护仪对st段异常位移的实时报警在减少ACS入院前的延误方面的有效性。 在ALERTS临床试验中,将907名ACS复发高风险患者随机分成对照组(无预警)和治疗组(有预警),最终发现有预警组的患者的延误时间更短,有55%的ACS事件在2h内转诊至急诊,而无预警组的仅10%(p < 0.0001

JACC:早发型冠心病的远期进展研究

早发冠心病(CAD)的远期发展规律尚不清楚。本研究的目的旨在描述年轻患者冠脉粥样硬化的发展规律和危险因素。本研究纳入分析了年龄≤45岁的急性或稳定梗阻性CAD患者,主要终点事件是全因死亡、心梗、需要冠状动脉血运重建的难治性心绞痛和缺血性中风。最终共纳入了880例早发CAD患者,平均年龄为 40.1±5.7岁,在基线水平时,91.2%的患者接受了冠脉血运重建,主要是由于急性心梗(78.8%)。经过超

JACC:性别特异性高敏肌钙蛋白试剂盒在急性冠脉综合征诊断中的应用

急性冠脉综合征在诊断、治疗和预后方面存在明显的性别差异,而高敏肌钙蛋白在诊断疑似急性冠脉综合征患者是否存在性别差异尚不清楚。本研究纳入分析了来自10家医院的疑似急性冠脉综合征患者,主要终点事件是1年后的心梗复发或者死亡。最终共纳入了48282名患者(女性占47%),通过高敏肌钙蛋白性别特异性诊断试剂盒,可以提高女性42%和男性6%的诊断率,有心肌损伤的女性较男性更少接受冠脉血运重建(15% vs.

JACC:升主动脉长度与主动脉瘤患者预后相关

升主动脉瘤的纵向变化少有人关注,本研究的目的旨在评估升主动脉瘤(ATAA)的自然病程以及升主动脉长度(AAL)。本研究纳入了522例ATAA患者,对其升主动脉直径、长度和远期不良主动脉事件(破裂、夹层和死亡)进行了评估。结果发现,与AAL<9 cm的患者相比,AAL≥13cm患者的不良主动脉事件发生风险要增高5倍以上。主动脉平均每年增长0.18cm,且与年龄呈独立相关。联合主动脉高度指数(A

盘点:JACC十月第3期研究一览

1.未经治疗的中重度主动脉瓣狭窄患者远期生存率低DOI: 10.1016/j.jacc.2019.08.004http://www.onlinejacc.org/content/74/15历史数据显示未接受治疗的主动脉瓣狭窄(AS)患者的生存率低主要局限于严重AS患者。本研究的目的旨在评估所有AS类型患者的预后。本研究纳入分析了测量过主动脉瓣流速和压差的122809名男性患者(平均年龄61±17岁

JACC:未经治疗的中重度主动脉瓣狭窄患者远期生存率低

历史数据显示未接受治疗的主动脉瓣狭窄(AS)患者的生存率低主要局限于严重AS患者。本研究的目的旨在评估所有AS类型患者的预后。本研究纳入分析了测量过主动脉瓣流速和压差的122809名男性患者(平均年龄61±17岁)和118494名女性患者(62±19岁),并排除之前接受过主动脉瓣干预治疗的患者。最终,共有16129名患者(6.7%)、3315名(1.4%)和6383名(2.6%)患者分别为轻度、中